J. Safra Asset Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

J. Safra Asset Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.23K	Buy	+30	New	+$6.57K	﹤0.01%	439
2016 Q4	–	Sell	-715	Closed	-$87K	–	79
2016 Q3	$87K	Hold	715	–	–	0.15%	36
2016 Q2	$101K	Buy	+715	New	+$105K	0.16%	57

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

J. Safra Asset Management's JAZZ Position: Q2 2026 in Review

J. Safra Asset Management opened a new position in Jazz Pharmaceuticals (JAZZ) in Q2 2026: 30 shares worth $7.23K. The stake represents ﹤0.01% of the portfolio and ranks #439 among its holdings. This is a return to the name: J. Safra Asset Management previously reported a position in JAZZ as recently as Q3 2016.

J. Safra Asset Management first reported a position in JAZZ in Q2 2016 and has held it in 3 quarters since. The position peaked at $101K in Q2 2016. 649 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

J. Safra Asset Management held 30 shares of Jazz Pharmaceuticals worth $7.23K as of Q2 2026.
Jazz Pharmaceuticals was a new J. Safra Asset Management position in Q2 2026.
Jazz Pharmaceuticals made up ﹤0.01% of J. Safra Asset Management's portfolio in Q2 2026, its #439 holding.
J. Safra Asset Management first reported a position in Jazz Pharmaceuticals in Q2 2016 and has held it in 3 quarters since.
J. Safra Asset Management's Jazz Pharmaceuticals position peaked at $101K in Q2 2016.
649 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on J. Safra Asset Management's 13F filing for Q2 2026, filed 6 Aug 2026.